Evidence map›Paper›PMID 42491312›Full record

ArticleJournal of clinical tuberculosis and other mycobacterial diseases2026

Performance of the BACES model in a Dutch cohort with nontuberculous mycobacterial pulmonary disease.

Arthur Lemson, Esmee van de Pol, Jakko van Ingen, Wouter Hoefsloot

Abstract read
In one paragraph

Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Arthur LemsonDepartment of Pulmonary Diseases, Research Institute for Medical Innovation, Radboud University Medical Center, Radboudumc Community for Infectious Diseases, Nijmegen, the Netherlands.
Esmee van de PolDepartment of Pulmonary Diseases, Research Institute for Medical Innovation, Radboud University Medical Center, Radboudumc Community for Infectious Diseases, Nijmegen, the Netherlands.
Jakko van IngenDepartment of Medical Microbiology, Radboudumc Community for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Wouter HoefslootDepartment of Pulmonary Diseases, Research Institute for Medical Innovation, Radboud University Medical Center, Radboudumc Community for Infectious Diseases, Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The BACES model, developed in South Korea, predicts all-cause mortality in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) using BMI, age, cavitary disease, erythrocyte sedimentation rate, and male sex. The total score categorizes patients into low, intermediate, or high mortality risk groups. We evaluated the performance of BACES in a Dutch cohort of patients with NTM-PD. Methods: This retrospective analysis included adults with NTM-PD between January 2008 and August 2019. Time to all-cause mortality was calculated from diagnosis. Performance of the original and modified BACES models were assessed using Kaplan-Meier curves, Harrell's C-statistic, and calibration curves. Cox regression identified independent mortality predictors. Results: We enrolled 183 patients (median age 63 years, 56% female), of whom 86.3% received antimycobacterial therapy. The median (IQR) follow-up time was 6.3 years (3.7-9.0) with 54.1% deaths. BACES risk scores categorized 118 patients: 23.7% low risk, 63.3% intermediate risk, and 12.7% high risk. Among risk groups, Kaplan-Meier curves demonstrated clear stratification (log-rank <0.001). Harrell's C-statistic and calibration curves were evaluated in 86 patients due to missing data. Harrell's C-statistic was 0.67 (95%CI, 0.57-0.76), indicating poor discrimination, but the calibration curve showed good agreement between predicted and observed mortality. After modifying the model by adjusting the ESR cut-off and replacing sex with COPD history, the C-statistic improved to 0.76 (95% CI 0.69-0.84). Conclusions: The BACES model proves useful for group-level risk stratification (e.g., low, intermediate high), but lacks precision in predicting individual prognosis in Dutch patients with NTM-PD. Modifications to the model enhanced its discriminatory performance.

Indexed as

All-cause mortalityBACES ModelExternal ValidationMycobacterium abscessusMycobacterium avium complex

Identifiers

PMID42491312
PMCPMC13377126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.